Health Care & Hospital Law,
Administrative/Regulatory
Jul. 25, 2018
Feds approve cannabis as epilepsy medicine in landmark ruling
The FDA's approval signals growing acceptance of cannabis, but increasing federal control could harm consumers and the industry.
James Raza Lawrence
Partner
Margolin & Lawrence
Email: raza@margolinlawrence.com
Raza is a founding partner of Margolin & Lawrence. The firm represents and advises cannabis businesses and individuals on compliance, licensing, zoning, criminal defense, and other matters at the local, state, and federal levels.
Allison B. Margolin
Allison B. Margolin PLCEmail: allison@allisonmargolin.com
Allison is a founding partner of Allison B. Margolin PLC. The firm represents and advises cannabis businesses and individuals on compliance, licensing, zoning, criminal defense, and other matters at the local, state, and federal levels.
On June 25, the Food and Drug Administration announced that it was approving Epidiolex, a cannabidiol (CBD) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy. This is the first drug approved by the FDA comprised of an active ingredient derived from marijuana.
The approval is a sign of the growing acceptance of CBD, and cannabis generally, to treat various medical ailments. THC, not CBD...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In